ReviewMolecular biomedicine2026
GLP-1/GLP-1R signalling in infectious diseases: basic biology, immunometabolic mechanisms, and therapeutic translation.
Review in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infectious diseases remain a major global health burden, and metabolic disorders such as diabetes and obesity further increase susceptibility to infection and adverse outcomes. These intersecting metabolic and infectious risks have prompted growing interest in the glucagon-like peptide-1 (GLP-1)/GLP-1 receptor (GLP-1R) axis beyond its established role in glycaemic regulation. GLP-1 receptor agonists (GLP-1RAs) modulate systemic metabolism, neuroimmune signalling, vascular and epithelial homeostasis, and inflammatory responses. Whether their infection-related effects arise from direct immune-cell GLP-1R signalling, improved pathogen control, or indirect host protection remains unresolved. This narrative review critically evaluates GLP-1/GLP-1R signalling in infection. It distinguishes live-pathogen models from endotoxin and sterile-injury models, host resistance from host tolerance, and direct receptor-dependent actions from indirect systemic effects. It also differentiates chronic pre-infection exposure from treatment initiated after infection onset. Across selected preclinical models, GLP-1RAs more consistently attenuate inflammation and tissue injury while preserving organ function, whereas their effects on pathogen burden and clearance remain variable. Receptor-specific evidence for immune-cell-intrinsic GLP-1R signalling remains limited, and many reported immune phenotypes may instead reflect metabolic improvement, neuroimmune regulation, or barrier protection. Human evidence is derived mainly from observational studies and secondary analyses of chronic GLP-1RA exposure, with limited evidence from trials initiating treatment during acute infection. Future translation will require cell-specific receptor validation, live-pathogen models with post-infection treatment, parallel assessment of pathogen control and host protection, clinically relevant standard-of-care comparators, and infection-specific safety evaluation. GLP-1RAs are therefore best regarded as candidate host-directed adjuncts. Current evidence does not establish them as direct anti-infective therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.